It’s not uncommon in my world to be engaged in very lively academic debates, like the risk versus benefits associated with new antidepressant drugs.  Similarly, I have been widely attacked by a variety of vested health interests, particularly when I have argued for the clear cost-benefits associated with the range of new health initiatives.

It is more unusual, however, to be openly criticised, via Twitter, by the editor of a leading medical journal -- particularly when that journal has just commissioned, peer-reviewed and published a major review that you have written. You can see here the Twitter feed of The Lancet’s editor, Richard Horton.